Almirall, S.A.

General ticker "LBTSF" information:

  • Sector: Health Care
  • Industry: Drug Manufacturers - Specialty & Generic
  • Capitalization: $2.4B (TTM average)

Almirall, S.A. follows the US Stock Market performance with the rate: 45.7%.

Estimated limits based on current volatility of 0.0%: low 15.35$, high 15.35$

Factors to consider:

  • Company pays dividends (irregularly): last record date 2025-05-16, amount 0.21$ (Y1.37%)

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [14.10$, 21.91$]
  • 2026-12-31 to 2027-12-31 estimated range: [13.75$, 21.68$]

Financial Metrics affecting the LBTSF estimates:

  • Positive: with PPE of 49.2 at the end of fiscal year the price was low
  • Positive: -4.75 < Operating profit margin, % of 6.11
  • Positive: -14.22 < Investing cash flow per share per price, % of -4.70
  • Positive: 42.68 < Shareholder equity ratio, % of 63.63 <= 64.29
  • Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 1.94
  • Positive: Inventory ratio change, % of -0.98 <= -0.75
  • Negative: negative Industry operating cash flow (median)
  • Positive: 0.01 < Operating cash flow per share per price, % of 5.98

Similar symbols

Short-term LBTSF quotes

Long-term LBTSF plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue €894.52MM €985.72MM €1,107.67MM
Operating Expenses €899.78MM €949.63MM €1,039.98MM
Operating Income €-5.26MM €36.09MM €67.69MM
Non-Operating Income €-11.93MM €-9.59MM €6.73MM
Interest Expense €7.21MM €17.00MM €17.85MM
R&D Expense €66.91MM €79.00MM €138.05MM
Income(Loss) €-17.19MM €26.50MM €74.42MM
Taxes €21.28MM €0.00MM €28.28MM
Profit(Loss)* €-38.47MM €10.15MM €46.18MM
Stockholders Equity €1,463.40MM €1,488.38MM €1,486.58MM
Inventory €167.37MM €171.69MM €178.07MM
Assets €2,374.99MM €2,396.66MM €2,336.26MM
Operating Cash Flow €93.48MM €160.77MM €169.14MM
Capital expenditure €159.30MM €161.43MM €34.90MM
Investing Cash Flow €-122.56MM €-140.04MM €-132.89MM
Financing Cash Flow €168.21MM €-31.58MM €-75.56MM
Earnings Per Share** €-0.20 €0.04 €0.22

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.